GU Oncology Now

?? A virtual roundtable hosted by Petros Grivas contextualized the latest #bladdercancer research updates and trials of relevancy to come out of American Society of Clinical Oncology (ASCO) #GU25. Dr. Grivas was joined by Drs. Guru Sonpavde, MD , Elizabeth Plimack , Christopher Wallis, Terry Friedlander, and Matthew Galsky: https://lnkd.in/eRtqY7Yj ?? In part 1, the impact of long-term survival data from the EV-302 trial is explored.

?? Patients with metastatic RCC with #Medicare have significantly better survival rates compared with patients who receive #Medicaid or have no insurance. ?? Learn more about a recent analysis of data from 2 National Cancer Institute (NCI)–designated cancer centers:

?? A roundtable of expert panelists including Drs. Dan Childs, Andrew Hahn, Cora Sternberg, and Vadim Koshkin were led by Tanya Dorff in a discussion on the latest research updates in #mHSPC. ?? The panel explores the the role of imaging, genomics, and patient factors: https://buff.ly/njVLm8f

?? We spoke with Alan Tan, MD of Vanderbilt University Medical Center on key insights from the #TALAPRO-2 trial and the OS benefit of #talazoparib + #enzalutamide in mCRPC. ?? He explores the synergy between PARP inhibitors and ARSIs, the role of HRR testing in patient selection, and more: https://buff.ly/4fFixAa

?? Watch our new roundtable on the latest research and practice updates related to advanced #kidneycancer. ?? Dr. Karine Tawagi was joined by Drs. Regina Barragán Carrillo, Benjamin Maughan , Laurence Albiges, and David McDermott for this insightful discussion: https://buff.ly/gdVA2UK

?? A recent study has sought to determine the clinical utility of #ctDNA in advanced #urothelial cancer by establishing and evaluating a plasma ctDNA sequencing assay. ?? Researchers examined the association between ctDNA fraction and response to #pembrolizumab, analyzing ctDNA dynamics throughout systemic therapy:

?? Germline genetic testing is underused for patients with #prostatecancer, despite many being eligible for the procedure. ?? A recent study explored perceptions and decision-making related to undergoing genetic testing among patients with prostate cancer to learn more about this discrepancy:

?? Katy Beckermann discusses the KEYMAKER-U03 substudy on #pembrolizumab and targeted therapy combos for previously treated advanced #ccRCC. ?? Learn about the outcomes of 3 different treatment regimens: pembrolizumab + belzutifan, lenvatinib + belzutifan, and pembrolizumab + lenvatinib: https://buff.ly/4kd8bX4

?? A panel on the evolving role of adjuvant therapy in #kidneycancer moderated by Katy Beckermann included guest experts David Braun, Matthew Campbell, Bradley McGregor, and Katie Murray in a discussion on patient selection criteria, the timing of therapy, and more: https://buff.ly/u0waNMo

?? In part 1 of a new roundtable moderated by Alan Bryce, expert panelists discuss advances in biomarker testing, treatment intensification, and best practices for integrating next-generation sequencing into clinical #prostatecancer care: https://buff.ly/6TYvvuL ?? The panel included Drs. Alan Tan, MD, Evan Yu, Priyanka Chablani, MD/MS, Jack Andrews, and chad tang.